ANTI-GAMMA MUTANT PROTEIN AGAINST ENDOGENOUS HUMAN INTERFERON- GAMMA

The invention relates to anti-gamma mutant protein against endogenous human gamma-interferon (hIFN-³) applicable for the treatment of diseases associated with increased production of endogenous hIFN-³. The anti-gamma mutant protein represents inactive hIFN-³ analogue with preserved affinity to the h...

Full description

Saved in:
Bibliographic Details
Main Authors TILEVA, Milena H, MASKOS, Klaus, NATCHEVA, Genoveva A, GRIGOLEIT, Patricia, KRACHMAROVA, Elena B, IVANOV, Ivan G
Format Patent
LanguageEnglish
French
German
Published 03.10.2018
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to anti-gamma mutant protein against endogenous human gamma-interferon (hIFN-³) applicable for the treatment of diseases associated with increased production of endogenous hIFN-³. The anti-gamma mutant protein represents inactive hIFN-³ analogue with preserved affinity to the hIFN-³ receptor, wherein the last five C-terminal amino acid residues of the interferon molecule are removed, the amino acid at position 88 is replaced with glutamine (Q) and additionally the amino acid at position 27 is replaced with tyrosine (Y) or the amino acid at position 41 is replaced with asparagine (N).
Bibliography:Application Number: EP20180472002